These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27270116)

  • 1. Myotonic dystrophy type 1.
    Nguyen CE; Campbell C
    CMAJ; 2016 Oct; 188(14):1033. PubMed ID: 27270116
    [No Abstract]   [Full Text] [Related]  

  • 2. Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy.
    Wahbi K; Bassez G; Duchateau J; Salort-Campana E; Vicart S; Desaphy JF; Labombarda F; Sellal JM; Deharo JC
    Arch Cardiovasc Dis; 2024; 117(6-7):450-456. PubMed ID: 38677940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Heatwole C; Luebbe E; Rosero S; Eichinger K; Martens W; Hilbert J; Dekdebrun J; Dilek N; Zizzi C; Johnson N; Puwanant A; Tawil R; Schifitto G; Beck CA; Richeson JF; Zareba W; Thornton C; McDermott MP; Moxley R
    Neurology; 2021 Jan; 96(2):e228-e240. PubMed ID: 33046619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1.
    Algalarrondo V; Wahbi K; Sebag F; Gourdon G; Beldjord C; Azibi K; Balse E; Coulombe A; Fischmeister R; Eymard B; Duboc D; Hatem SN
    Neuromuscul Disord; 2015 Apr; 25(4):308-20. PubMed ID: 25613807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voltage-Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues.
    Catalano A; Franchini C; Carocci A
    Curr Med Chem; 2021; 28(8):1535-1548. PubMed ID: 32364065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age and causes of death in adult-onset myotonic dystrophy.
    de Die-Smulders CE; Höweler CJ; Thijs C; Mirandolle JF; Anten HB; Smeets HJ; Chandler KE; Geraedts JP
    Brain; 1998 Aug; 121 ( Pt 8)():1557-63. PubMed ID: 9712016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
    Groh WJ
    Neurology; 2011 Jan; 76(4):409; author reply 409. PubMed ID: 21263144
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome.
    Maury P; Audoubert M; Cintas P; Rollin A; Duparc A; Mondoly P; Chiriac AM; Acket B; Zhao X; Pasquié JL; Cardin C; Delay M; Sadron M; Carrié D; Galinier M; Davy JM; Arne-Bès MC; Raczka F
    Heart Rhythm; 2014 Oct; 11(10):1721-7. PubMed ID: 25016148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Dystrophic and Nondystrophic Myotonias.
    Sansone VA
    Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1889-1915. PubMed ID: 27922499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment of incontinence of feces in myotonic muscular dystrophy by mexiletine].
    Hayashi T; Ichiyama T; Tanaka H; Koga M; Okino A
    No To Hattatsu; 1991 May; 23(3):310-2. PubMed ID: 2043377
    [No Abstract]   [Full Text] [Related]  

  • 11. What is the best way to detect infra-Hisian conduction abnormalities and prevent sudden cardiac death in myotonic dystrophy?
    Duboc D; Wahbi K
    Heart; 2012 Mar; 98(6):433-4. PubMed ID: 22350028
    [No Abstract]   [Full Text] [Related]  

  • 12. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
    Logigian EL; Martens WB; Moxley RT; McDermott MP; Dilek N; Wiegner AW; Pearson AT; Barbieri CA; Annis CL; Thornton CA; Moxley RT
    Neurology; 2010 May; 74(18):1441-8. PubMed ID: 20439846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myotonic dystrophy.
    Tramonte JJ; Burns TM
    Arch Neurol; 2005 Aug; 62(8):1316-9. PubMed ID: 16087777
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables.
    Cudia P; Bernasconi P; Chiodelli R; Mangiola F; Bellocci F; Dello Russo A; Angelini C; Romeo V; Melacini P; Politano L; Palladino A; Nigro G; Siciliano G; Falorni M; Bongiorni MG; Falcone C; Mantegazza R; Morandi L
    J Neurol Neurosurg Psychiatry; 2009 Jul; 80(7):790-3. PubMed ID: 19237383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arrhythmia exacerbation after sodium channel blockade in myotonic dystrophy type 1.
    Otten RF; Scherschel JA; Lopshire JC; Bhakta D; Pascuzzi RM; Groh WJ
    Muscle Nerve; 2009 Nov; 40(5):901-2. PubMed ID: 19623641
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular effects of mexiletine for treatment of myotonia in myotonic dystrophy type 1.
    Salguero-Bodes R; Ruiz-Curiel A; Palomino-Doza J; Valverde-Gómez M; Domínguez-González C; Arribas-Ynsaurriaga F
    Rev Esp Cardiol (Engl Ed); 2021 Nov; 74(11):986-987. PubMed ID: 34120884
    [No Abstract]   [Full Text] [Related]  

  • 17. Inheritance and pathogenicity of myotonic dystrophy.
    Johnson K
    Mol Cell Biol Hum Dis Ser; 1993; 3():85-110. PubMed ID: 8111546
    [No Abstract]   [Full Text] [Related]  

  • 18. Ambulatory electrocardiographic monitoring in type 1 myotonic dystrophy.
    Sá MI; Cabral S; Costa PD; Coelho T; Freitas M; Gomes JL
    Rev Port Cardiol; 2007; 26(7-8):745-53. PubMed ID: 17939583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The problem of diagnosis and therapy of myotonic dystrophy].
    Reisecker F; Markut H; Tulzer W
    Wien Med Wochenschr; 1983 Jun; 133(12):319-21. PubMed ID: 6613149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle Channelopathies.
    Suetterlin KJ; Bugiardini E; Kaski JP; Morrow JM; Matthews E; Hanna MG; Fialho D
    JAMA Neurol; 2015 Dec; 72(12):1531-3. PubMed ID: 26658970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.